| __timestamp | Travere Therapeutics, Inc. | Vericel Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 59644696 | 13774000 |
| Thursday, January 1, 2015 | 79541000 | 22479000 |
| Friday, January 1, 2016 | 98015000 | 27388000 |
| Sunday, January 1, 2017 | 103958000 | 35610000 |
| Monday, January 1, 2018 | 103654000 | 49007000 |
| Tuesday, January 1, 2019 | 128951000 | 61139000 |
| Wednesday, January 1, 2020 | 135799000 | 68836000 |
| Friday, January 1, 2021 | 149883000 | 97592000 |
| Saturday, January 1, 2022 | 220206000 | 106903000 |
| Sunday, January 1, 2023 | 265542000 | 120998000 |
Igniting the spark of knowledge
In the competitive landscape of biotechnology, understanding spending patterns is crucial. Over the past decade, Vericel Corporation and Travere Therapeutics, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Travere Therapeutics' SG&A expenses surged by approximately 345%, peaking in 2023. This reflects a strategic investment in growth and market expansion. In contrast, Vericel Corporation's SG&A expenses increased by about 780% during the same period, indicating a robust scaling of operations. Notably, in 2023, Travere's SG&A expenses were more than double those of Vericel, highlighting differing operational strategies. These trends underscore the dynamic nature of financial management in the biotech sector, where strategic spending can be a key driver of competitive advantage.
AbbVie Inc. or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?
BeiGene, Ltd. vs Vericel Corporation: SG&A Expense Trends
Neurocrine Biosciences, Inc. and Vericel Corporation: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Jazz Pharmaceuticals plc and Travere Therapeutics, Inc.
Comparing SG&A Expenses: Grifols, S.A. vs Travere Therapeutics, Inc. Trends and Insights
Rhythm Pharmaceuticals, Inc. and Vericel Corporation: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Veracyte, Inc. and Vericel Corporation
Comparing SG&A Expenses: Vericel Corporation vs Merus N.V. Trends and Insights
Who Generates Higher Gross Profit? Vericel Corporation or Travere Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Vericel Corporation and Supernus Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Dynavax Technologies Corporation and Travere Therapeutics, Inc.
Taro Pharmaceutical Industries Ltd. or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?